Side-by-side comparison of AI visibility scores, market position, and capabilities
NYSE-listed (PHR) patient intake platform digitizing check-in for 4,000+ practices at $383M revenue; pharma-funded activation programs competing with Epic and Clearwave for healthcare front-office engagement.
Phreesia is a Raleigh, North Carolina-based patient intake and engagement platform — listed on NYSE (NYSE: PHR) — providing healthcare practices, health systems, and pharmaceutical companies with digital tools for patient registration, insurance verification, payment collection, clinical pre-screening, and patient activation. Founded in 2005 by Chaim Indig and Evan Roberts and generating $383 million in revenue in fiscal year 2025 (ending January 2025), Phreesia serves 4,000+ healthcare practices and health systems with the patient-facing digital infrastructure that replaces paper clipboards and manual front-desk registration.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.